On October 9, 2018 AVEO Oncology (NASDAQ:AVEO) reported that updated interim data from the Phase 2 portion of the TiNivo trial of tivozanib and nivolumab (OPDIVO) in advanced renal cell carcinoma will be presented at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) 2018 Annual Congress being held October 19-23, 2018 in Munich, Germany (Press release, AVEO, OCT 9, 2018, View Source [SID1234529825]). The TiNivo study is a Phase 1b/2 multicenter trial of oral tivozanib (FOTIVDA) in combination with intravenous nivolumab (OPDIVO, Bristol-Myers Squibb), an immune checkpoint, or PD-1, inhibitor, for the treatment of metastatic renal cell carcinoma (mRCC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The accepted abstract, which includes results from a poster presentation at the 2018 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium in January, is available via the ESMO (Free ESMO Whitepaper) 2018 Annual Congress website. Updated data will be presented at the ESMO (Free ESMO Whitepaper) conference.

Presentation Details

Title: TiNivo: Tivozanib combined with nivolumab: safety and efficacy in patients with metastatic renal cell carcinoma (mRCC)
Presenter: Philippe Barthelemy, Medical Oncology Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, FR
Presentation Number: 878P
Date and Time: October 22, 2018, 1:05 p.m. CEST
Location: Hall A3 – Poster Area